Therapeutic strategies combining BRAF inhibitors with agents targeting eIF4F have demonstrated the ability to overcome most resistance pathways that emerge in cancers carrying the BRAF (V600) mutation such as melanoma, colon and thyroid cancers. Here, BRAF is linked to thyroid cancer.